Company intelligence / Profile preview

BioGenCell

Netanya, Central District, Israelbiogencell.net ↗

Ownership: Private
Development stage: Phase 2

Overview

BioGenCell has developed a unique, autologous stem cell-based therapy platform for microvascular diseases. Its lead product, BCG101, targets critical limb ischemia (CLI), showing promising first-in-human clinical trial results including wound healing, improved walking ability, pain reduction, and enhanced quality of life one year post-treatment. The company is currently advancing through Phase II clinical trials.

Therapeutic areas: Cardiovascular
Modalities: Cellular therapiesStem cell therapy (autologous stem cells from patient’s own blood)
Industry: Biotech

Drug pipeline

2 assets

BGC101

1 more asset in the full pipeline.

Request access →

Partnerships

Strategic partnership with Laniado Hospital in Netanya, Israel

Beyond the preview

Go deeper on BioGenCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioGenCell.

Explore the full profile